Abstract: Cardiac resynchronization therapy with biventricular pacing is an established therapy for heart failure patients with sinus rhythm, reduced left ventricular ejection fraction and electrical ventricular desynchronization. The aim of the study was to evaluate electrical interventricular delay and left ventricular delay in right ventricular pacemaker pacing before upgrading to cardiac resynchronization therapy. Heart failure patients with right ventricular pacing, DDD pacemaker, DDD defibrillator and 24.5 ± 4.9 % left ventricular ejection fraction were measured by surface ECG and transesophageal bipolar left ventricular ECG before upgrading to cardiac resynchronization therapy. Interventricular and intraventricular desynchronization in right ventricular pacemaker pacing were 228.2 ± 44.8ms QRS duration, 86.5 ± 32.8ms interventricular delay and 94.4 ± 23.8ms left ventricular delay. Cardiac resynchronization therapy was optimized by impedance cardiography. Transesophageal electrical interventricular delay and left ventricular delay in right ventricular pacemaker pacing may be additional useful ventricular desynchronization parameters to improve patient selection for upgrading right ventricular pacemaker pacing to cardiac resynchronization therapy.
Introduction
Cardiac resynchronization therapy with biventricular pacing is an established therapy for heart failure patients with sinus rhythm, reduced left ventricular ejection fraction and electrical interventricular and intraventricular desynchronization [1, 2] . Transesophageal focused ECG allow the non-invasive evaluation of electrical interventricular delay [3] [4] [5] .
The aim of the study was to evaluate electrical interventricular delay, left ventricular delay and the ratio between QRS duration and interventricular delay in right ventricular pacemaker and defibrillator pacing before upgrading to cardiac resynchronization therapy with biventricular pacing.
Methods
Eleven heart failure patients with dual chamber DDD pacemaker in ten patients, dual chamber DDD defibrillator in one patient, right ventricular pacing, New York Heart Association class 3.0 ± 0.2 and 24.5 ± 4.9 % left ventricular ejection fraction were measured by surface ECG and transesophageal bipolar left ventricular ECG before upgrading to cardiac resynchronization therapy defibrillator in eight patients and cardiac resynchronization therapy pacemaker in three patients. The mean age of one female and ten males was 69.0 ± 7.9 years. Electrical interventricular delay was measured between onset of QRS in the surface ECG and onset of left ventricular signal in the transesophageal ECG. Electrical left ventricular delay was measured between onset and offset of left ventricular signal in the transesophageal ECG (see Figure 1 ). Cardiac resynchronization therapy atrioventricular delay after atrial sensing and atrial pacing were optimized by transthoracic impedance cardiography.
Statistical analysis was performed by Origin® 2017 software (OriginLab Corporation, Northampon, MA, USA) using paired and unpaired t-tests, as appropriate, with a statistical significance of p<0.05 and with Pearson correlation coefficients.
Electromagnetic simulation was performed with CST STUDIO SUITE® (CST -Computer Simulation Technology, Darmstadt).
Results
Evaluation of electrical interventricular delay and left ventricular delay was possible in eleven heart failure patients with right ventricular pacemaker or defibrillator pacing. Transesophageal posterior left atrial and left ventricular ECG was recorded in ten patients with dual chamber DDD pacemaker and in one patient with dual chamber DDD defibrillator.
Electrical interventricular desynchronization
Electrical interventricular and left ventricular desynchronization in right ventricular pacemaker pacing were 228.2 ± 44.8ms QRS duration, 86.5 ± 32.8ms interventricular delay, 94.4 ± 23.8ms left ventricular delay, 2.6 ± 0.8 QRSduration to interventricular delay ratio with correlation between interventricular delay and QRS duration to interventricular delay ratio (r=-0.668 P=0.0248) and 2.3 ± 0.7 QRS duration to left ventricular delay ratio (see Figure 2 ). 
Left ventricular ejection fraction
The left ventricular ejection fraction to electrical interventricular delay ratio was 0.3 ± 0.1 with correlation between electrical interventricular delay and left ventricular ejection fraction to electrical interventricular delay ratio (r=-0.8063 P=0.00272) and with correlation between QRS duration and left ventricular ejection fraction to electrical interventricular delay (r=-0.7251 P=0.01157) (see Figure 3 ). 
Cardiac resynchronization therapy
Optimal atrioventricular delay after atrial sensing and atrial pacing were 128.3 ± 24.8ms atrioventricular delay after atrial sensing in six patients and 173.3 ± 40.4ms atrioventricular delay after atrial pacing in three patients (see Figure 4) . During 30.4 ± 29.6 month cardiac resynchronization therapy follow-up, the New York Heart Association class improved from 3.1 ± 0.2 to 2.2 ± 0.3 (see Figure 5 ). 
Discussion
Stipdonk and co-workers evaluated the electrical ventricular delay between onset of QRS complex and left ventricular lateral wall activation in patients with non-specific intraventricular conduction delay with EnSite NavX electroanatomical mapping [6] . Electrical interventricular delay with telemetric left ventricular ECG was a good predictor for the evaluation of cardiac resynchronization therapy responder and non-responder in heart failure patients with sinus rhythm [1] . The evaluation of transesophageal interventricular delay was possible with focused transesophageal left ventricular ECG in heart failure patients with sinus rhythm [3] .
Transesophageal electrical interventricular delay and left ventricular delay in right ventricular pacemaker pacing may be additional useful ventricular desynchronization parameters to improve patient selection for upgrading right ventricular pacemaker pacing to cardiac resynchronization therapy.
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